|Day Low/High||14.28 / 15.39|
|52 Wk Low/High||12.75 / 28.88|
Let's drill down on the charts of this global healthcare company.
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
Disney, Qualcomm and Square are among 75 key reports we are watching.
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
What new management means for Mylan shareholders moving forward.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.